BGLC BioNexus Gene Lab Corp
Services-Medical Laboratories · Nasdaq · SEC CIK 1737523 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-67.3%
TTM net income YoY12.2%
TTM EPS YoY-27.7%
Revenue 3-yr CAGR-32.9%
Net income 3-yr CAGR—
Margins
Gross margin12.3%
Operating margin-81.8%
Net margin-82.4%
FCF margin-27.3%
EBITDA margin-78.2%
Returns
ROE-33.7%
ROA-28.4%
ROIC (approx.)-32.3%
Asset turnover0.34x
Leverage & solvency
Liabilities / assets10.9%
Debt / equity0.00x
Current ratio6.08x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.33x
Accruals ratio-19.1%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $7.42M | $9.51M | $9.77M | $10.93M | $13.36M |
| Cost of revenue | $6.34M | $8.22M | $8.44M | $9.67M | $11.10M |
| Gross profit | $1.09M | $1.29M | $1.33M | $1.26M | $2.27M |
| R&D expense | $50,670 | $47,511 | $54,982 | — | — |
| SG&A expense | $1.54M | $1.83M | $2.44M | $1.73M | $1.28M |
| Operating income | -$2.97M | -$1.57M | -$2.59M | -$291,177 | $1.06M |
| Interest expense | — | — | $13,929 | $12,479 | — |
| Pretax income | -$2.98M | -$1.59M | -$2.61M | -$303,656 | $1.04M |
| Income tax | $0 | -$3,494 | -$21,526 | -$52,310 | -$291,283 |
| Net income | -$2.98M | -$1.60M | -$2.63M | -$355,966 | $751,571 |
| EBITDA | -$2.85M | -$1.47M | -$2.51M | -$199,750 | $1.15M |
| EPS (diluted) | — | -0.09 | -0.17 | — | — |
| Weighted avg. shares (diluted) | — | 17.82M | 15.88M | — | — |
| Banking | |||||
| Net interest income | — | — | $8,877 | $7,794 | — |
| Balance sheet | |||||
| Cash & equivalents | $2.38M | $2.89M | $4.52M | $2.12M | $2.12M |
| Receivables | $505,885 | $1.38M | — | — | — |
| Inventory | $676,703 | $1.39M | $1.14M | $977,807 | $1.52M |
| Current assets | $5.45M | $7.43M | $8.05M | $6.02M | $7.15M |
| PP&E, net | $1.60M | $1.52M | $1.51M | $1.51M | $1.63M |
| Total assets | $9.25M | $10.43M | $11.40M | $8.74M | $9.57M |
| Current liabilities | $520,957 | $1.95M | $1.63M | $2.00M | $2.33M |
| Total liabilities | $637,856 | $2.11M | $1.74M | $2.08M | $2.39M |
| Shareholders' equity | $8.61M | $8.32M | $9.66M | $6.67M | $7.18M |
| Shares outstanding | 2.42M | 1.80M | 17.67M | 14.48M | 171.22M |
| Cash flow statement | |||||
| Operating cash flow | -$1.84M | -$2.09M | -$1.82M | $551,822 | $9,161 |
| Capital expenditure | $36,971 | $226,989 | $149,398 | $0 | $3,162 |
| Free cash flow | -$1.88M | -$2.32M | -$1.97M | $551,822 | $5,999 |
| Investing cash flow | $944,751 | $418,202 | -$1.79M | -$450,498 | -$490,574 |
| Financing cash flow | $298,841 | $3,975 | $6.27M | $108,168 | -$28,222 |
| Depreciation & amortization | $111,873 | $104,160 | $83,253 | $91,427 | $91,282 |
| Stock-based compensation | $794,770 | $141,000 | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.